Sciele has acquired from Summers Laboratories the rights to this novel, patented product in the US, Canada and Mexico. The company expects to launch the product in the third quarter of 2009.
Ed Schutter, president and COO of Sciele Pharma, said: “We are excited to introduce this novel product to the prescription head lice treatment market. This product will meet the unmet need for an effective treatment that does not contain a neurotoxic chemical and addresses possible resistance issues. The approval of this new head lice product marks an important milestone for Sciele’s pediatric portfolio.”